The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)
As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Joseph, Philip [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Bimetallic diffusion modeling and temperature regulation during ball milling - Aureli, Matteo ELSEVIER, 2018, JACC, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:74 ; year:2019 ; number:5 ; day:6 ; month:08 ; pages:672-682 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jacc.2019.04.067 |
|---|
| Katalog-ID: |
ELV047448970 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047448970 | ||
| 003 | DE-627 | ||
| 005 | 20230626015659.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2019.04.067 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000702.pica |
| 035 | |a (DE-627)ELV047448970 | ||
| 035 | |a (ELSEVIER)S0735-1097(19)35452-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Joseph, Philip |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. | ||
| 520 | |a As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. | ||
| 650 | 7 | |a coronary artery disease |2 Elsevier | |
| 650 | 7 | |a heart failure |2 Elsevier | |
| 650 | 7 | |a beta-blockers |2 Elsevier | |
| 700 | 1 | |a Swedberg, Karl |4 oth | |
| 700 | 1 | |a Leong, Darryl P. |4 oth | |
| 700 | 1 | |a Yusuf, Salim |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Aureli, Matteo ELSEVIER |t Bimetallic diffusion modeling and temperature regulation during ball milling |d 2018 |d JACC |g New York, NY |w (DE-627)ELV000161896 |
| 773 | 1 | 8 | |g volume:74 |g year:2019 |g number:5 |g day:6 |g month:08 |g pages:672-682 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jacc.2019.04.067 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 74 |j 2019 |e 5 |b 6 |c 0806 |h 672-682 |g 11 | ||
| author_variant |
p j pj |
|---|---|
| matchkey_str |
josephphilipswedbergkarlleongdarrylpyusu:2019----:heouinflcesnooayreyiesad |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
51.00 51.32 |
| publishDate |
2019 |
| allfields |
10.1016/j.jacc.2019.04.067 doi GBV00000000000702.pica (DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Joseph, Philip verfasserin aut The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2019transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier Swedberg, Karl oth Leong, Darryl P. oth Yusuf, Salim oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 https://doi.org/10.1016/j.jacc.2019.04.067 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 74 2019 5 6 0806 672-682 11 |
| spelling |
10.1016/j.jacc.2019.04.067 doi GBV00000000000702.pica (DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Joseph, Philip verfasserin aut The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2019transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier Swedberg, Karl oth Leong, Darryl P. oth Yusuf, Salim oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 https://doi.org/10.1016/j.jacc.2019.04.067 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 74 2019 5 6 0806 672-682 11 |
| allfields_unstemmed |
10.1016/j.jacc.2019.04.067 doi GBV00000000000702.pica (DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Joseph, Philip verfasserin aut The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2019transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier Swedberg, Karl oth Leong, Darryl P. oth Yusuf, Salim oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 https://doi.org/10.1016/j.jacc.2019.04.067 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 74 2019 5 6 0806 672-682 11 |
| allfieldsGer |
10.1016/j.jacc.2019.04.067 doi GBV00000000000702.pica (DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Joseph, Philip verfasserin aut The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2019transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier Swedberg, Karl oth Leong, Darryl P. oth Yusuf, Salim oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 https://doi.org/10.1016/j.jacc.2019.04.067 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 74 2019 5 6 0806 672-682 11 |
| allfieldsSound |
10.1016/j.jacc.2019.04.067 doi GBV00000000000702.pica (DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X DE-627 ger DE-627 rakwb eng 600 690 VZ 51.00 bkl 51.32 bkl Joseph, Philip verfasserin aut The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) 2019transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier Swedberg, Karl oth Leong, Darryl P. oth Yusuf, Salim oth Enthalten in Elsevier Aureli, Matteo ELSEVIER Bimetallic diffusion modeling and temperature regulation during ball milling 2018 JACC New York, NY (DE-627)ELV000161896 volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 https://doi.org/10.1016/j.jacc.2019.04.067 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 74 2019 5 6 0806 672-682 11 |
| language |
English |
| source |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 |
| sourceStr |
Enthalten in Bimetallic diffusion modeling and temperature regulation during ball milling New York, NY volume:74 year:2019 number:5 day:6 month:08 pages:672-682 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
coronary artery disease heart failure beta-blockers |
| dewey-raw |
600 |
| isfreeaccess_bool |
false |
| container_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| authorswithroles_txt_mv |
Joseph, Philip @@aut@@ Swedberg, Karl @@oth@@ Leong, Darryl P. @@oth@@ Yusuf, Salim @@oth@@ |
| publishDateDaySort_date |
2019-01-06T00:00:00Z |
| hierarchy_top_id |
ELV000161896 |
| dewey-sort |
3600 |
| id |
ELV047448970 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047448970</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2019.04.067</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000702.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047448970</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(19)35452-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Joseph, Philip</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">coronary artery disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">beta-blockers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swedberg, Karl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leong, Darryl P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yusuf, Salim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:5</subfield><subfield code="g">day:6</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:672-682</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2019.04.067</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2019</subfield><subfield code="e">5</subfield><subfield code="b">6</subfield><subfield code="c">0806</subfield><subfield code="h">672-682</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| author |
Joseph, Philip |
| spellingShingle |
Joseph, Philip ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier heart failure Elsevier beta-blockers The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| authorStr |
Joseph, Philip |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000161896 |
| format |
electronic Article |
| dewey-ones |
600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
600 690 VZ 51.00 bkl 51.32 bkl The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) coronary artery disease Elsevier heart failure Elsevier beta-blockers Elsevier |
| topic |
ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier heart failure Elsevier beta-blockers |
| topic_unstemmed |
ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier heart failure Elsevier beta-blockers |
| topic_browse |
ddc 600 bkl 51.00 bkl 51.32 Elsevier coronary artery disease Elsevier heart failure Elsevier beta-blockers |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k s ks d p l dp dpl s y sy |
| hierarchy_parent_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| hierarchy_parent_id |
ELV000161896 |
| dewey-tens |
600 - Technology 690 - Building & construction |
| hierarchy_top_title |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000161896 |
| title |
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| ctrlnum |
(DE-627)ELV047448970 (ELSEVIER)S0735-1097(19)35452-X |
| title_full |
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| author_sort |
Joseph, Philip |
| journal |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| journalStr |
Bimetallic diffusion modeling and temperature regulation during ball milling |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
672 |
| author_browse |
Joseph, Philip |
| container_volume |
74 |
| physical |
11 |
| class |
600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Joseph, Philip |
| doi_str_mv |
10.1016/j.jacc.2019.04.067 |
| dewey-full |
600 690 |
| title_sort |
evolution of β-blockers in coronary artery disease and heart failure (part 1/5) |
| title_auth |
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| abstract |
As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. |
| abstractGer |
As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. |
| abstract_unstemmed |
As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
5 |
| title_short |
The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) |
| url |
https://doi.org/10.1016/j.jacc.2019.04.067 |
| remote_bool |
true |
| author2 |
Swedberg, Karl Leong, Darryl P. Yusuf, Salim |
| author2Str |
Swedberg, Karl Leong, Darryl P. Yusuf, Salim |
| ppnlink |
ELV000161896 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.jacc.2019.04.067 |
| up_date |
2024-07-06T22:54:48.640Z |
| _version_ |
1803872096633225216 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047448970</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626015659.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jacc.2019.04.067</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000702.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047448970</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0735-1097(19)35452-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Joseph, Philip</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5)</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As new treatments continue to improve clinical outcomes in coronary artery disease (CAD) and heart failure, it is necessary to characterize the appropriate use of β-adrenergic receptor blockers (β-blockers) in the contemporary management of these conditions. This review examines the current evidence supporting β-blocker use in heart failure with preserved ejection fraction (HFpEF), heart failure with midrange ejection fraction (HFmEF), and heart failure with reduced ejection fraction (HFrEF), following acute coronary syndrome and in stable CAD. β-Blockers remain essential in the treatment of HFrEF, but limited evidence supports their use in HFmEF or HFpEF. They should still be considered routinely following acute coronary syndrome, but there is a need for contemporary trials that re-examine this in patients without left ventricular dysfunction, as well as in patients with stable CAD. From a global perspective, more studies are needed to characterize the extent of β-blocker use in CAD and heart failure, and how evidence-based use can be improved in these conditions.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">coronary artery disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">heart failure</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">beta-blockers</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Swedberg, Karl</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Leong, Darryl P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yusuf, Salim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Aureli, Matteo ELSEVIER</subfield><subfield code="t">Bimetallic diffusion modeling and temperature regulation during ball milling</subfield><subfield code="d">2018</subfield><subfield code="d">JACC</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV000161896</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:74</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:5</subfield><subfield code="g">day:6</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:672-682</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jacc.2019.04.067</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">74</subfield><subfield code="j">2019</subfield><subfield code="e">5</subfield><subfield code="b">6</subfield><subfield code="c">0806</subfield><subfield code="h">672-682</subfield><subfield code="g">11</subfield></datafield></record></collection>
|
| score |
7.4002113 |